Despite promising Phase II data, there was no difference in overall survival between the patients who received Canvaxin and the patients who received placebo in the randomized Phase III trial of ...

Skin is an attractive target for delivery of genetic therapies and vaccines. However, new approaches are needed to access this tissue more effectively. Here, we describe a new delivery technology ...